Similarly, the activity level of immune-related pathways such as TGF beta signaling pathway, chemokine signaling pathway, and intestinal network for IgA production, has been proven to be associated with GC treatment and prognosis [56–58], our research results also confirmed significant differences in these pathways between the C1 and C2 subtypes, validating the accuracy of the GC classification model based on parthanatos scores that we constructed. The gene discussed is CD79A; the disease is gastric cancer.